Article ; Online: Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis.
2017 Volume 49, Issue 10, Page(s) 2256–2259
Abstract: Background: Few data exist on recurrence rates, treatment response, and long-term outcomes in kidney transplant recipients (KTR) with primary focal segmental glomerulosclerosis (FSGS).: Methods: This retrospective, observational study included 1218 ... ...
| Abstract | Background: Few data exist on recurrence rates, treatment response, and long-term outcomes in kidney transplant recipients (KTR) with primary focal segmental glomerulosclerosis (FSGS). Methods: This retrospective, observational study included 1218 consecutive KTR during 2002 to 2016. All patients with primary idiopathic FSGS were identified through application of strict diagnostic criteria. Outcomes were followed over an average of 70.4 months. Results: We identified 48 KTR (3.9%) with primary FSGS. Seven-year death-censored graft survival rate was 81% (primary FSGS) versus 85% (control) (P = .297). Eighteen KTR had FSGS recurrence (predicted incidence, 50% after 7 years). Seven-year death-censored graft survival rate in KTR with FSGS recurrence was significantly worse than in FSGS KTR without recurrence (63% versus 96%, P = .010). In the case of FSGS recurrence, a multi-modal treatment approach was applied, including plasma exchange (PE) (100% of patients), intravenous cyclosporine (50%), rituximab (61%), and the "Multiple Target Treatment" (39%). The median number of PE sessions was 27. Proteinuria decreased significantly and persistently during the course of treatment. Complete remission of FSGS was observed in 7 patients (39%); another 7 patients (39%) had partial remission (PE dependence was observed in 4 patients [22%]). Four patients (22%) with FSGS recurrence had early graft loss (<6 months after transplant) despite all treatment efforts. Conclusions: In KTR with primary FSGS, a high proportion of recurrence occurred, and recurrence was associated with significantly worse death-censored graft survival rates. However, a multi-modal treatment approach led to improvement of proteinuria and full or partial remission in most patients. Importantly, overall death-censored graft survival rate in KTR with primary FSGS was comparable with that in the control group. |
|---|---|
| MeSH term(s) | Adult ; Combined Modality Therapy ; Cyclosporine/administration & dosage ; Female ; Glomerulosclerosis, Focal Segmental/complications ; Glomerulosclerosis, Focal Segmental/mortality ; Glomerulosclerosis, Focal Segmental/therapy ; Graft Survival ; Humans ; Immunologic Factors/administration & dosage ; Kidney Transplantation/methods ; Kidney Transplantation/mortality ; Male ; Middle Aged ; Plasma Exchange/methods ; Postoperative Period ; Proteinuria/etiology ; Proteinuria/therapy ; Recurrence ; Remission Induction ; Retrospective Studies ; Rituximab/administration & dosage ; Survival Rate ; Treatment Outcome |
| Chemical Substances | Immunologic Factors ; Rituximab (4F4X42SYQ6) ; Cyclosporine (83HN0GTJ6D) |
| Language | English |
| Publishing date | 2017-12 |
| Publishing country | United States |
| Document type | Journal Article ; Observational Study |
| ZDB-ID | 82046-5 |
| ISSN | 1873-2623 ; 0041-1345 |
| ISSN (online) | 1873-2623 |
| ISSN | 0041-1345 |
| DOI | 10.1016/j.transproceed.2017.10.001 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 835: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.